The Association between Ranitidine Use and Gastrointestinal Cancers

Area of Science:

• Gastroenterology
• Oncology
• Pharmacovigilance

Background:

• N-nitrosodimethylamine (NDMA) is a probable human carcinogen found in ranitidine.
• Ranitidine is an H2 antagonist used to reduce stomach acid.
• NDMA contamination raises concerns about ranitidine's safety profile.

Purpose of the Study:

• To evaluate the association between ranitidine use and gastrointestinal system cancers.
• To compare cancer risk in ranitidine users versus users of proton pump inhibitors (PPIs) and other H2 antagonists.
• To investigate the potential link between NDMA-contaminated ranitidine and cancer development.

Main Methods:

• Analysis of FDA Adverse Events Reporting System data.
• Calculation of Proportionate Reporting Ratios (PRRs) and 95% Confidence Intervals (CIs).
• Comparison of gastrointestinal cancer event proportions for ranitidine versus other acid-reducing medications.

Main Results:

• Ranitidine use showed an elevated risk for overall gastrointestinal cancers (PRR 3.66).
• Significant increased risks were observed for pharyngeal, esophageal, stomach, colorectal, liver, and pancreatic cancers.
• Elevated, though not statistically significant, risks were noted for anal and gallbladder cancers.

Conclusions:

• Study findings support the hypothesis that NDMA-contaminated ranitidine increases cancer risk.
• Results suggest a need for withdrawal of ranitidine medications from the market.
• Further research corroborates the link between NDMA in ranitidine and increased cancer incidence.